NY: Pharmacia & Upjohn Co; 2010
NY: Pharmacia & Upjohn Co; 2010. elements. Results. Altogether, 1,550 individuals with first-line mCRC had been enrolled (median follow-up, 21 weeks) & most received FOLFOXCbevacizumab (= 968) or FOLFIRICbevacizumab (= 243) as first-line therapy. The baseline characteristics and median treatment…